ArticleScientific reports2025
Berberine hydrochloride inhibits the proliferation and metastasis of p53 mutant gallbladder Cancer cells by regulating the IL6/STAT3 pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Berberine Chloride Suppresses Growth of Canine Osteosarcoma Cells via Regulating MMP2/AKT/β-Catenin Pathway.Antioxidants (Basel, Switzerland) · 2026Article
- The JAK/STAT pathway: a pivotal therapeutic target in disease and advances in natural product modulation.Molecular diversity · 2026Review
- IL-6/STAT3 signaling pathway-mediated apoptosis induced by medical ozone water in liver cancer: A mechanistic study.Biomedical reports · 2026Article
- Parenteral Berberine vs Cisplatin- Loaded Lipid Nanoparticles - Development, Characterisation, Comparative Safety Profiling and Cytotoxicity in Cholangiocarcinoma Cell Models.Nanotechnology, science and applications · 2026Article
- Roles of Selected Bioactive Compounds in Inhibiting the Development and Progression of Cancer-A Review.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Gallbladder cancer (GBC) is one of the most common biliary malignancies. Berberine hydrochloride, an compound extracted from the traditional Chinese medicinal plant Coptis chinensis, has potential therapeutic effects on various tumor cells. Therefore, we aimed to characterize the anticancer efficacy of berberine hydrochloride in the context of GBC. Methods: We evaluated the effects of berberine hydrochloride on cell viability, cell cycle progression, apoptosis, metastasis and invasion in the p53 mutant GBC-SD and p53 wild-type NOZ cell lines. Next, we investigated the mechanism underlying the effects of berberine hydrochloride on GBC cells via analysis of a human apoptosis proteome profiler array and a human inflammation array, and we confirmed the mechanism. Furthermore, we analyzed the ability of berberine hydrochloride to inhibit tumor formation in a liver xenograft model. Results: Berberine hydrochloride influenced the cell proliferation, apoptosis, cytoskeletal arrangement, metastasis and invasion of GBC cells, especially p53-mutant GBC-SD cells, by reducing interleukin-6 and p-STAT3 expression, triggering an inflammatory response resulting in apoptosis induction via caspase-3, caspase-8, and XIAP. Conclusion: In GBC cells, berberine hydrochloride inhibited the IL-6/STAT3 pathway and then induced apoptosis, ultimately exerting various biological effects. This study provides new insights for therapeutic targets in GBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.